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Abstract
Background: The increasing push to commercialize university research has emerged as a significant science policy
challenge. While the socio-economic benefits of increased and rapid research commercialization are often emphasized
in policy statements and discussions, there is less mention or discussion of potential risks. In this paper, we highlight
such potential risks and call for a more balanced assessment of the commercialization ethos and trends.
Discussion: There is growing evidence that the pressure to commercialize is directly or indirectly associated with
adverse impacts on the research environment, science hype, premature implementation or translation of research
results, loss of public trust in the university research enterprise, research policy conflicts and confusion, and damage to
the long-term contributions of university research.
Summary: The growing emphasis on commercialization of university research may be exerting unfounded pressure
on researchers and misrepresenting scientific research realities, prospects and outcomes. While more research
is needed to verify the potential risks outlined in this paper, policy discussions should, at a minimum, acknowledge
them.
Keywords: Commercialization, Pressure to commercialize, Applied research, Knowledge translation, Risks versus
benefits, Science hype, Ethics, Science policy, University research, Science funding
Background
The university research community has always been under
various forms of outside pressure – political, economic,
and institutional – that has had the potential to impact,
for better or worse, the nature and direction of academic
research. And, of course, researchers bring their own
biases, ambitions and tendencies to their work. Academic
research is rarely, if ever, truly pure.
In recent years, however, a new type of pressure has
descended on university-based research by way of in-
creased emphasis on the commercialization of research
[1–6]. The political mandate that pushes for this shift
seems qualitatively different from other pressures. It is
not only ubiquitous [1, 4], but it has also been urged,
framed and promoted at the highest levels of policy-
making [1, 2, 4]. To cite one high profile example,
President Obama has enthusiastically endorsed using
academic research to drive economic growth in his last
two State of the Union Addresses [7, 8] and in other
recent speeches [4, 9, 10], and has remarked that
“[t]wenty-first century businesses will rely on American
science and technology, research and development [7].
Other world leaders have honed in on the message as
well [1, 11]; Prime Minister Stephen Harper of Canada
has stated, for example, that a primary aim of scientific
research is to “power” commerce [12].
Two areas where the push for increased commer-
cialization of university-based research appear particu-
larly evident are research funding and program support.
In Canada, for example, there are very few research
funding opportunities that are not touched by the
commercialization ethos [1]. If researchers want funding,
they will now need to frame their work in a manner that
accords with the growing political view that universities
ought to play a central role in the growth of economies
[13, 14], or to accord with national or regional economic
priorities [1, 15, 16]. With regard to program support,
universities are facing increased pressure to cut pro-
grams that do not generate revenue as a way of dealing
with budgetary constraints. As recently stated by a
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Canadian provincial finance minister in a budget presen-
tation speech, universities must “preserve…high value
programs and, correspondingly….identify and shed low-
value programs that do not represent good return on in-
vestment” [17].
Studies of research policy trends suggest that the
commercialization ethos and associated pressures are
unlikely to relent anytime soon [14] and may, in fact,
become the central or defining mission of university-
based research. These studies also show that the push
to commercialize is almost always presented as an un-
qualified social good [1] that warrants broad governmental
and institutional focus and support [13]. Conversely, the
goals and endpoints of the commercialization push are
not well articulated, if at all, and its potential risks and
challenges are largely absent from policy statements and
discussions [1].
This paper highlights the potential risks associated
with the commercialization ethos. While many of these
risks outlined below require further research to confirm
their existence and impacts in connection with the
push to commercialize, we are of the view that, at the
very least, they should be part of the public and policy
dialogue about the role that commercialization should
or ought to play in shaping and influencing the direc-
tion and focus of university-based research. The risks
presented below are by no means exhaustive, or neces-
sarily specific to research commercialization trends. How-
ever, they provide critical starting points for a more
balanced reflection on the commercialization imperative.
Discussion
Before engaging with the potential risks of the push to
commercialize university research, it is important to ac-
knowledge and highlight some of the benefits and ad-
vantages associated with the trend. Commercialization
is a primary means through which medical products
and services reach the market and consumers, which
can, in turn, advance public health. Also, research
commercialization initiatives can, in theory, generate
interest and investment in emerging areas of research,
with consequent gains or improvements in research
funding, job creation, scope and quality of innovation,
creation and growth of industries, and economic sus-
tainability of universities [3, 18, 19]. Commercialization
can also help build university-industry collaborations
that are often necessary for the translation of research
into beneficial products and therapies for public use.
While a critical or extensive engagement with the
positive outcomes of commercialization are beyond the
scope of this paper, we acknowledge that there are
well established and observed impacts of research
commercialization that justify its relevance to research/
science policy and society in general. In particular, it is
worth noting that our analysis neither touches upon nor
seeks to diminish any positive effects associated with the
“entrepreneurial university” [20, 21], or the established
role of commercialization in advancing university-
industry-government relationships (i.e., the “triple helix”
concept) [22].
While the afore-mentioned benefits are often upheld
in policy documents and discussions as justifications for
increased commercialization, they are either expressed
in broad aspirational terms or as axiomatic endpoints,
and often with little or no evidence orreasoned reflection
in support [1, 4, 23]. Moreover, evidence of a link be-
tween university research and economic growth is tenu-
ous at best [4, 23, 24], and the discussion of some
potential benefits, such as increased industry participa-
tion in research translation, fail to acknowledge or dis-
cuss established and potential risks, such as risks
associated with the data reporting and publication prac-
tices in industry funded research.
Potential risks
Adverse impacts on research environment
Two distinct impacts on the research environment arise
in connection with commercialization pressure, namely
impacts on the direction and type of research being done,
and impacts on research practices. Regarding the former,
recent studies of the impact of commercialization pressure
on the research environment suggest that the trend is
viewed unfavourably by many in the research community,
and is associated with a variety of adverse effects on the
conduct, integrity or direction of research [25–27]. For ex-
ample, a 2014 Pew Research Center survey of members of
American Association for the Advancement of Science,
which is the world’s largest general scientific association,
found that nearly half (47 %) believed that the pres-
sure to develop marketable products was having an
undue influence on the direction of their research,
while a majority (69%) viewed a focus on projects ex-
pected to yield rapid results as having a similar influ-
ence on their research [28]. Another study, from
2014, concluded that the “government-initiated em-
phasis on commercialization” of U.S. university re-
search “may undermine open paths toward novel
technologies and hinder explorations of unknown
fields” [29]. A small study of members of the Canadian
stem cell research community found similar views and
concerns, and that a majority of those surveyed (76 %)
either agree or strongly agree that commercialization and
translation pressure could impact public trust or funding
of their research [1]. In relation to impacts on research
practices, several studies have found or posited associa-
tions between commercialization activity and data with-
holding [30–32], the erosion of collaborative research
relationships [33, 34] and reluctance or unwillingness to
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engage in certain research trends, such as open science
initiatives, which seemingly conflict with the financial con-
siderations that underlie the pursuit of commercialization
[29, 35–37].
Science hype
There is growing concern that representations of bio-
medical research are inappropriately overstated, in-
cluding in scientific abstracts [38], institutional press
releases [39], newspaper coverage of research [40],
and in popular culture more broadly. There are, of
course, many sources of science “hype” that work in
concert to produce exaggerated representations, in-
cluding publication pressures and public, media and
institutional expectations [41]. It is, no doubt, a com-
plex problem involving many actors. But given that
the commercialization mandate requires science that
can be translated quickly and that will have practical
results, it seems likely it is a pressure that is, at least,
playing a role in this trend. Some of the concerns
associated with science hype include exaggerated pub-
lic and patient expectations, misinformed science and
health policy, and the possibility of loss of public sup-
port where promised outcomes do not materialize
[42–44]. Science hype can also be exploited by those
seeking to market unproven and potentially harmful
therapies. Lastly, participation by researchers in pro-
moting or advocating for the commercial potential of
their work, especially if tied to success in obtaining
research grants, could skew the framing of research
questions and outcomes in a manner that compro-
mises their ability to approach the research from a
disinterested position.
Premature implementation and use of services
A commonly held view among advocates of the push to
commercialize is that research activities, particularly in
the biomedical and medical sciences, can and ought to
yield near-term commercializable products and services
for clinical use [1, 2]. While there is a possibility that this
position is mere rhetorical flourish in support of argu-
ments for the increasing policy emphasis on transla-
tional research, one thing is clear: the view does not
accord with any realistic assessment of the process and
duration of translational research. Research results do
not materialize according to a set schedule or in re-
sponse to the expectations and demands of the market.
Studies, especially of the biomedical and clinical research
context, suggest that moving from bench to market
takes decades [45, 46], and only few among many re-
search studies yield more than modest direct returns or
useful products or services [2, 46, 47]. Even the process
of regulatory scrutiny and approval takes years.
Given this reality, the notion that “fast and successful”
translation of research results is possible and desirable, es-
pecially when expressed by prominent policymakers, may
skew research incentives and public expectations in favour
of premature implementation of research results, with
consequent risks to research integrity and to the quality,
safety or efficacy of research outputs [13, 48]. Indeed,
commercialization activities and associated incentives
have been linked to premature implementation of
gene therapy research programs [49]. In the stem cell
research context, a global market for putative, scien-
tifically unproven stem cell therapies has emerged,
and appears to be expanding in availability and reach
despite evidence of considerable health, financial,
regulatory and social risks posed by the phenomenon
[50–54]. While it remains unclear how the “near-term
translation and commercialization” ethos factors into
or drives the market for unproven and unapproved
stem cell therapies, the phenomenon is arguably a re-
sponse to the commercialization message.
Regarding public expectation, the view that near-
term translation is possible and achievable, coupled
with offerings of premature products and services,
may shift public perception of the translational re-
search process or lead to public demand for faster ac-
cess to research outputs. This may, in turn, create a
challenge for regulators both in terms of responding
to access demands and justifying regulatory rules and
decisions. In the United States, for example, the Food
and Drug Administration has recently been forced to
use litigation and enforcement orders and notices to
deal with premature implementation issues arising in part
from consumer demand for stem cell-based products and
services [55–58].
Public trust
The effect of the commercialization ethos on public
trust is less likely to be direct and more consequen-
tial to the materialization of some of the afore-
discussed risks, such as where overstated research
benefits fail to emerge or premature products and
services cause harm to the members of the public.
However, there is evidence to suggest that commercial
considerations negatively affect public perceptions of
research, and may have a role to play in the erosion
of public support of research and the acceptance of
research results [59–62]. In this regard, several aca-
demic commentators and research studies have noted
or found associations between commercialization ac-
tivities and declining public trust in research. For ex-
ample, a recent Australian study of public views of
stem cell research concluded that “the results of this
research clearly highlight the importance of trust in
public support for stem cell research, and that the
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commercial research context is a significant threat to
this trust” [59]. The study also found that “[r]egard-
less of where scientists source their cells, public sup-
port and trust are eroded when their work is
conducted in a private research organisation using
private funds” [59]. Similarly, a 2012 study of over
1000 Albertans found that, in the context of tissue
research, public trust in university research erodes
quickly if there are ties to industry [63]. Whether
direct or consequential, the potential for loss of pub-
lic trust is arguably the most pressing risk associated
with the drive to commercialize. Given the role that
public trust plays in relation to setting research pri-
orities, agenda and in the allocation of research re-
sources, loss of public confidence and trust will
most likely doom an affected area of research, or at
least create significant setbacks [49, 64]. Indeed, the
push toward commercialization seems to be happening
at the worst possible time, when public trust in the trad-
itional sources of science is eroding [65]. The further
commercialization of university-based research will only
exacerbate this dilemma.
Skewed health policy
The commercialization agenda clearly favours prod-
ucts and services that can generate economic activity,
such as marketable tests, interventions and drugs. This
approach arguably has little to do with addressing broader
socio-economic and behavioural changes that would have
broader and more enduring impact on human health [66].
The potential for harm caused by the push toward com-
mercially oriented technological approaches – at the ex-
pense of a focus on social change – has been noted by
numerous commentators in the context of a range of
emerging technologies – including genetic testing [67],
personalized medicine [66], nutrigenomics [68], epigenet-
ics [48] and stem cell research [13]. As noted by Petersen
and Krisjansen, “[i]ncreasing investment in the promissory
life sciences, including the harnessing of the publicly
funded resources of universities and other publicly funded
research institutions, means that fewer resources are avail-
able for social research and policy initiatives in areas of
pressing need” [48]. Given that research on prevention,
public health and behaviour intervention already receives
far less government funding than research aimed toward
treatment [69], such pressure can hardly be viewed as
constructive.
Other studies have found that the emphasizing a com-
mercializable, technological approach to health problems
may also have an adverse impact on the development of
social policy. It has been found, for example, that fram-
ing health issues, such as obesity, as being a disease as-
sociated with genetics – a framing that is more likely
when commercialization is the goal – as opposed to a
social problem demanding social reforms, leads to less
support for government public health policies [70, 71].
In addition, commercialization may result in clinical
trends – such as a push toward more testing and screen-
ing procedures – that conflict with other, evidence-
based, approaches to healthcare, such as the recent
push to do less diagnostic screening in an effort to
avoid unnecessary harm, anxiety and costs [72]. And, of
course, the push to commercialize may also lead to in-
crease healthcare costs, as the introduction of new
technologies almost inevitably do – an ironic conclu-
sion, given that economic benefit is one of the stated
benefits of the commercialization agenda.
Damage to the long-term economic contributions of
university research
The notion that university research should and ought
to focus on near-term translational research activities
that produce commercializable products and services
may obliterate support for other long-term contribu-
tions to basic and clinical research that produce both
incremental and ground-breaking advances [2, 14].
While this may not in fact be a huge loss if the near-term
commercialization strategy is successful (but they rarely, if
ever, are), there is little reason to suppose that simply re-
ducing the time for research and development will yield
more contributions for the financial or knowledge econ-
omies. As one well-known Canadian commentator has
noted, for example, the money generated by the intellec-
tual property owned by Canadian universities is minuscule
[24]. After accounting for the direct costs associated with
the management of commercialization activities, the total
surplus for all Canadian universities for 2010 amounted to
$2.1 million, and the average income for each university
as was only $425,000. This is hardly the kind of money
that will drive economies and change the fate of univer-
sities. Besides, a focus on near-term commercialization
goals may alter research behaviour and incentives and lead
to negative impacts on the knowledge economy, such as
increased publication and translation of research of di-
luted value [73, 74] and shifts away from new ideas that
require basic research [75].
Conclusions
There are interesting questions about the degree to
which the concerns we note above can be supported by
empirical evidence. For example, to what degree is
commercialization pressure adding to science hype and
a shift in health policy? These are intriguing issues that
warrant further research. But regardless, the concerns
noted have sufficient empirical backing to suggest that
are, at least, worthy of consideration. Indeed, the con-
cerns outlined above have at least as much supporting
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evidence as the alleged benefits of commercialization
and translation pressure. While there has been some
acknowledgement and discussion of the risks or trade-
offs associated with commercialization, especially in the
academic literature, there remains a notable lack of em-
phasis in the public and policy discussion, at least com-
pared to the emphasis on benefits. The discussion of
risks also appears missing in other relevant contexts,
such as within university settings. As such, our modest
recommendation is that these, and other concerns, be
an explicit part of the public, policy and institutional
debates surrounding the commercialization of science.
There is also a need to highlight and promote established
strategies for minimizing commercialization risks, such as
increased and better monitoring of university-industry re-
lationships, mechanisms to reduce research hype, in-
creased government funding of independent research and
the use of independent grant review mechanisms to test
and mitigate commercialization claims.
Summary
−University researchers are facing increased political
and institutional pressure to focus on commercializable
research and to rapidly commercialize their research
outcomes.
−The push or pressure to commercialize is ubiquitous,
and is often presented as an unqualified social good
that deserves unique governmental and institutional
focus and support.
−There is growing evidence of potential risks flowing
from or associated with the push to commercialize, but
consideration of such risks are largely absent from
policy statements and discussions.
−While more research is needed to confirm the existence
of these potential risks, they should, at a minimum,
be part of the public and political dialogue about the
role of commercialization in shaping the focus and
direction of university research.
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